ArticleCancer cell2021
Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.
Open access · greenAbstract read
In one paragraph
Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 199 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
199citing papers in PubMed, 1 pooled it
14.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
199 citing papers in PubMed, 1 synthesis or guideline pooled it, 321 citations in OpenAlex.
- Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.Frontiers in immunology · 2022Pooled it
- Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma.Journal for immunotherapy of cancer · 2026Trial
- Knowledge mapping and research trends of chimeric antigen receptor T-cell immunotherapy in breast cancer: A bibliometric and visual analytics study.Human vaccines & immunotherapeutics · 2026Article
- Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.Experimental hematology & oncology · 2026Review
- Targeting KRAS reprograms a Treg-dominant immunosuppressive microenvironment and sensitizes KRAS-mutant gastric adenocarcinoma to CTLA-4 immunotherapy.Science China. Life sciences · 2026Article
- Impact of spatial distribution of M2 macrophages on prognosis and neoadjuvant chemotherapy resistance in gastric cancer.Journal of gastrointestinal oncology · 2026Article
- IFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma.Nature communications · 2026Article
- Adoptive cell therapies in thoracic malignancies: a comprehensive review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases.Nature cancer · 2026Article
- A bibliometric and visualized analysis of CAR-T or TCR-T in solid tumor (from 2015 to 2024).Discover oncology · 2026Article
- A tumor-on-a-chip for in vitro study of CAR-T cell immunotherapy in solid tumors.Nature biotechnology · 2026Article
- The Conflicting Role of Myeloid Cells in CAR T-Cell Therapy.Cancer research · 2026Review
- The in vivo revolution in CAR-T therapy medicinal products: challenges and regulatory prospects.Signal transduction and targeted therapy · 2026Review
- Coincident epithelial signals restrain commensal-specific CD8αβbioRxiv : the preprint server for biology · 2026Article
- CAR immune cell therapy strategies and advances for lung cancer.Discover oncology · 2026Review
- Optimizing next-generation CAR-macrophages against solid tumors: challenges and potential strategies.Journal of hematology & oncology · 2026Review
- Oncofetal reprogramming in hepatocellular carcinoma: linking developmental programs to cancer vaccines and immunotherapy.Clinical and molecular hepatology · 2026Review
- Integrated analysis identifies a CXCR6/CD45/PD-1-based risk model for melanoma prognosis and intratumoral CD8+/CD69 + T-cell infiltration correlation.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Modulating AP-1 enables CAR T cells to establish an intratumoral stemlike reservoir and overcomes resistance to PD-1 blockade.Science immunology · 2026Article
- Hepatic arterial infusion chemotherapy (HAIC) combined with sequential or concurrent systemic targeted immunotherapy for advanced hepatocellular carcinoma: a single-center retrospective study.World journal of surgical oncology · 2026Review
139 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
20 authors at 4 institutions in 2 countries.
Shivani SrivastavaClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: ssrivas2@fredhutch.org.
Scott N FurlanClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA.
Carla A Jaeger-RuckstuhlClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Megha SarvothamaClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Carolina BergerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Kimberly S SmytheClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Sarah M GarrisonClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jennifer M SpechtClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA.
Sylvia M LeeClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA.
Robert A AmezquitaVaccine and Infections Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Valentin VoilletVaccine and Infections Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Vishaka MuhunthanClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Sushma Yechan-GunjaClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Smitha P S PillaiDepartment of Comparative Medicine, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Christoph RaderDepartment of Immunology and Microbiology, Scripps Research Institute, Jupiter, FL, USA.
A McGarry HoughtonClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Robert H PierceClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Raphael GottardoVaccine and Infections Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
David G MaloneyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA.
Stanley R RiddellClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA.
Fred Hutch Cancer Center · USUniversity of Washington · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAScripps Research Institute · US
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4MProject 4: Risk stratification for pulmonary nodules detected by CT imaging using plasma and imaging biomarkersP50CA228944 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI David MacPherson · 2019 to 2026
$19.6MTARGETING ROR1 WITH CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLSR01CA114536 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Sylvain Simon · 2005 to 2026
$8.4MNCI NIH HHS P30 CA015704NCI NIH HHS P50 CA228944NCI NIH HHS R01 CA114536
Abstract
Adoptive therapy using chimeric antigen receptor-modified T cells (CAR-T cells) is effective in hematologic but not epithelial malignancies, which cause the greatest mortality. In breast and lung cancer patients, CAR-T cells targeting the tumor-associated antigen receptor tyrosine kinase-like orphan receptor 1 (ROR1) infiltrate tumors poorly and become dysfunctional. To test strategies for enhancing efficacy, we adapted the Kras
Indexed as
AnimalsAntigens, NeoplasmCell LineCell Line, TumorHEK293 CellsHumansImmune Checkpoint InhibitorsImmunotherapy, AdoptiveLung NeoplasmsMiceMice, Inbred BALB CMice, Inbred C57BLReceptors, Antigen, T-CellReceptors, Chimeric AntigenReceptor Tyrosine Kinase-like Orphan ReceptorsT-LymphocytesAntigens, NeoplasmImmune Checkpoint InhibitorsReceptors, Antigen, T-CellReceptors, Chimeric AntigenReceptor Tyrosine Kinase-like Orphan Receptorsalveolar macrophageCAR-T cellsCXCR3CXCR6immunogenic cell deathKPlung adenocarcinomaoxaliplatinROR1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.